Adaptive Biotechnologies (ADPT) Short-term Investments (2018 - 2026)

Adaptive Biotechnologies has disclosed Short-term Investments across 9 years of filings, most recently posting $174.4 million for Q2 2026.

• In Q2 2026, Short-term Investments rose 12.72% year-over-year to $174.4 million; the TTM figure through Jun 2026 stood at $174.4 million (up 12.72% YoY), while the FY2025 annual figure was $156.5 million, down 10.26% from the prior year.
• Short-term Investments came in at $174.4 million for Q2 2026 at Adaptive Biotechnologies, up from $140.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $408.2 million in Q4 2022 to a low of $140.8 million in Q1 2026.
• Average Short-term Investments over 5 years is $236.0 million, with a median of $234.8 million recorded in 2024.
• The largest YoY upside for Short-term Investments was 90.74% in 2022 against a maximum downside of 53.99% in 2022.
• Over 5 years, Short-term Investments stood at $408.2 million in 2022, then sank by 31.07% to $281.3 million in 2023, then tumbled by 38.02% to $174.4 million in 2024, then slipped by 10.26% to $156.5 million in 2025, then advanced by 11.44% to $174.4 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $174.4 million in Q2 2026, $140.8 million in Q1 2026, and $156.5 million in Q4 2025.